**Supplementary Material**

*In vitro* and *in silico* evaluation of the anti-leishmanial activity of novel synthetic chalcones

Fernando Ferreira Leite 1, Luis Cezar Rodrigues2, Bruno Hanrry Melo de Oliveira1, Gabrielly Diniz Duarte2, Maria Denise Leite Ferreira1, Natália Ferreira de Sousa 1, Shayenne Eduarda Ramos Vanderley1,3, Leonardo Lima Cardoso1,3, Tatjana Souza Lima Keesen1,3, Rodrigo Santos Aquino de Araújo1,4, Luciana Scotti1, Marcus Tullius Scotti1, and Francisco Jaime Bezerra Mendonça-Junior 1,4,\*

1 Programa de Pós-Graduação em Produtos Bioativos Naturais e Sintéticos, Universidade Federal da Paraíba,

João Pessoa 58051-900, Brasil; [fernandoferreira\_15@hotmail.com](mailto:fernandoferreira_15@hotmail.com) (F.F.L.); [hanrygb@hotmail.com](mailto:hanrygb@hotmail.com) (B.H.M.O); [denisecaiana@yahoo.com.br](mailto:denisecaiana@yahoo.com.br) (M.D.L.F.); [nataliafsousa@ltf.ufpb.br](mailto:nataliafsousa@ltf.ufpb.br) (N.F.d.S.);[luciana.scotti@gmail.com](mailto:luciana.scotti@gmail.com) (L.S); [mtscotti@gmail.com](mailto:mtscotti@gmail.com) (M.T.S); [rodrigosantosbiologojp@gmail.com](mailto:rodrigosantosbiologojp@gmail.com) (R.S.A.A); [franciscojaime@servidor.uepb.edu.br](mailto:franciscojaime@servidor.uepb.edu.br) (F.J.B.M.-J)

2 Programa de Pós-Graduação em Desenvolvimento e Inovação de Fármacos e Medicamentos, Universidade Federal da Paraíba, João Pessoa 58051-900, Brasil; [luiscezarodrigues@acedmico.ufpb.br](mailto:luiscezarodrigues@acedmico.ufpb.br) (L.C.R.); [gabriellydduarte@hotmail.com](mailto:gabriellydduarte@hotmail.com) (G.D.D.);

3 Laboratório de Imunologia de Doenças Infecciosas do Departamento de Biologia Celular e Molecular; Universidade Federal da Paraíba, João Pessoa 58051-900, PB, Brasil; [shayenne.erv@gmail.com](mailto:Shayenne.erv@gmail.com) (S.E.R.V.); [leo\_cardoso.l@hotmail.com](mailto:leo_cardoso.l@hotmail.com) (L.L.C.); [tatkeesen@cbiotec.ufpb.br](mailto:tatkeesen@cbiotec.ufpb.br) (T.S.L.K.)

4 Laboratório de Síntese e Drug Delivery, Departamento de Ciências Biológicas, Universidade Estadual da Paraíba, João Pessoa 58071-160, Brasil \* Correspondência: [franciscojaime@servidor.uepb.edu.br](mailto:franciscojaime@servidor.uepb.edu.br) (F.J.B.M.-J)

**\*** Correspondence: franciscojaime@servidor.uepb.edu.br

**List of Figures**

[Figure 1: Chalcones synthesized via Claisen condensation. 2](#_Toc140682018)

[Figure 2: 1H RMN (CDCl3, 400 MHz) Compound 1 (**CP01**). 3](#_Toc140682019)

[Figure 3: 13C RMN (CDCl3, 100 MHz) Compound 1 (**CP01**) 4](#_Toc140682020)

[Figure 4: 1H RMN (CDCl3, 400 MHz) Compound 2 (**CP02**) 5](#_Toc140682021)

[Figure 5: 13C RMN (CDCl3, 100 MHz) Compound 2 (**CP02**) 5](#_Toc140682022)

[Figure 6: Mass spetrum HRMS (ESI-TOF+) Compound CP02. 6](#_Toc140682023)

[Figure 7: 1H RMN (CDCl3, 400 MHz) Compound 3 (**CP03**) 6](#_Toc140682024)

[Figure 8: 13C RMN (CDCl3, 100 MHz) Compound 3 (**CP03**) 7](#_Toc140682025)

[Figure 9: 1H RMN (CDCl3, 400 MHz) Compound 4 (**CP04**) 8](#_Toc140682026)

[Figure 10: 13C RMN (CDCl3, 100 MHz) Compound 4 (**CP04**) 8](#_Toc140682027)

[Figure 11: Mass spetrum HRMS (ESI-TOF+) Compound CP04. 9](#_Toc140682028)

[Figure 12: 1H RMN (CDCl3, 400 MHz) Compound 5 (**CP05**) 9](#_Toc140682029)

[Figure 13: 13C RMN (CDCl3, 100 MHz) Compound 5 (**CP05**) 10](#_Toc140682030)

[Figure 14: Mass spetrum HRMS (ESI-TOF+) Compound CP05. 10](#_Toc140682031)

[Figure 15: 1H RMN (CDCl3, 400 MHz) Compound 6 (**CP06**) 11](#_Toc140682032)

[Figure 16: 13C RMN (CDCl3, 100 MHz) Compound 6 (**CP06**) 12](#_Toc140682033)

[Figure 17: Mass spetrum HRMS (ESI-TOF+) Compound CP06. 12](#_Toc140682034)

[Figure 18: 1H RMN (CDCl3, 400 MHz) Compound 7 (**CP07**) 13](#_Toc140682035)

[Figure 19: 13C RMN (CDCl3, 100 MHz) Compound 7 (**CP07**) 13](#_Toc140682036)

[Figure 20: Mass spetrum HRMS (ESI-TOF+) Compound CP07. 14](#_Toc140682037)

[Figure 21: 1H RMN (CDCl3, 400 MHz) Compound 8 (**CP08**) 14](#_Toc140682038)

[Figure 22: 13C RMN (CDCl3, 100 MHz) Compound 8 (**CP08**) 15](#_Toc140682039)

[Figure 23: Mass spetrum HRMS (ESI-TOF+) Compound **CP08**. 15](#_Toc140682040)

[Figure 24: 1H RMN (CDCl3, 400 MHz) Compound 9 (**CP09**) 16](#_Toc140682041)

[Figure 25: 13C RMN (CDCl3, 100 MHz) Compound 9 (**CP09**) 16](#_Toc140682042)

[Figure 26: Mass spetrum HRMS (ESI-TOF+) Compound **CP09**. 17](#_Toc140682043)

[Figure 27: 1H RMN (CDCl3, 400 MHz) Compound 10 (**CP10**) 17](#_Toc140682044)

[Figure 28: 13C RMN (CDCl3, 100 MHz) Compound 10 (**CP010**) 18](#_Toc140682045)

[Figure 29: Mass spetrum HRMS (ESI-TOF+) Compound **CP10**. 18](#_Toc140682046)

[Figure 30: Graph of antileishmanial activity of compounds CP03, CP04 e CP06. 19](#_Toc140682047)

Figure 1: Chalcones synthesized via Claisen condensation.




Figure 2: 1H RMN (CDCl3, 400 MHz) Compound 1 (**CP01**).




Figure 3: 13C RMN (CDCl3, 100 MHz) Compound 1 (**CP01**)


**

Figure 4: 1H RMN (CDCl3, 400 MHz) Compound 2 (**CP02**)




Figure 5: 13C RMN (CDCl3, 100 MHz) Compound 2 (**CP02**)




Figure 6: Mass spetrum HRMS (ESI-TOF+) Compound CP02.




Figure 7: 1H RMN (CDCl3, 400 MHz) Compound 3 (**CP03**)




Figure 8: 13C RMN (CDCl3, 100 MHz) Compound 3 (**CP03**)




Figure 9: 1H RMN (CDCl3, 400 MHz) Compound 4 (**CP04**)




Figure 10: 13C RMN (CDCl3, 100 MHz) Compound 4 (**CP04**)




Figure 11: Mass spetrum HRMS (ESI-TOF+) Compound CP04.




Figure 12: 1H RMN (CDCl3, 400 MHz) Compound 5 (**CP05**)




Figure 13: 13C RMN (CDCl3, 100 MHz) Compound 5 (**CP05**)



Figure 14: Mass spetrum HRMS (ESI-TOF+) Compound CP05.




Figure 15: 1H RMN (CDCl3, 400 MHz) Compound 6 (**CP06**)



Figure 16: 13C RMN (CDCl3, 100 MHz) Compound 6 (**CP06**)




Figure 17: Mass spetrum HRMS (ESI-TOF+) Compound CP06.




Figure 18: 1H RMN (CDCl3, 400 MHz) Compound 7 (**CP07**)




Figure 19: 13C RMN (CDCl3, 100 MHz) Compound 7 (**CP07**)




Figure 20: Mass spetrum HRMS (ESI-TOF+) Compound CP07.




Figure 21: 1H RMN (CDCl3, 400 MHz) Compound 8 (**CP08**)




Figure 22: 13C RMN (CDCl3, 100 MHz) Compound 8 (**CP08**)




Figure 23: Mass spetrum HRMS (ESI-TOF+) Compound **CP08**.




Figure 24: 1H RMN (CDCl3, 400 MHz) Compound 9 (**CP09**)




Figure 25: 13C RMN (CDCl3, 100 MHz) Compound 9 (**CP09**)




Figure 26: Mass spetrum HRMS (ESI-TOF+) Compound **CP09**.




Figure 27: 1H RMN (CDCl3, 400 MHz) Compound 10 (**CP10**)




Figure 28: 13C RMN (CDCl3, 100 MHz) Compound 10 (**CP010**)




Figure 29: Mass spetrum HRMS (ESI-TOF+) Compound **CP10**.




Figure 30: Graph of antileishmanial activity of compounds CP03, CP04 e CP06.

